Rimegepant idiki molecule inhibitor yecalcitoningene-related peptide (CGRP) receptor inovhara kuita kweCGRP, ine simba vasodilator inotendwa kuita basa mumigraine misoro. Rimegepant inotenderwa kurapwa kweacute migraine kurwisa. Mumiedzo yekiriniki, rimegepant yaiwanzotenderwa zvakanaka nezviitiko zvisingawanzoitiki zvenguva pfupi serum aminotransferase kukwidziridzwa panguva yekurapa uye pasina zviitiko zvakashumwa zvekukuvara kwechiropa.

Rimegepant mupikisi wemuromo weCGRP receptor yakagadzirwa neBiohaven Pharmaceuticals. Yakagamuchira mvumo yeFDA munaFebruary 27, 2020 yeacute kurapwa migraine musoro. Kunyange zvazvo vadzivisi vakawanda veCGRP uye receptor yavo vakabvumirwa kurapa migraine (eg [erenumab], [fremanezumab], [galcanezumab]), rimegepant uye [ubrogepant] ndidzo chete nhengo dzemhuri ye "gepants" yemishonga yasara mukuvandudzwa, uye ndivo chete vanopikisa CGRP vane oral bioavailability. Iyo yazvino chiyero chemigraine therapy inosanganisira kubvisa nhumbu ne "triptans", senge [sumatriptan], asi mishonga iyi inopesana nevarwere vane cerebrovascular uye chirwere chemwoyo chisati chavapo nekuda kwevasoconstrictive properties. Antagonism yeCGRP nzira yave chinangwa chinokwezva chemigraine therapy sezvo, kusiyana ne triptans, oral CGRP vanopikisa havana kucherechedzwa vasoconstrictive properties uye saka yakachengeteka kushandiswa kune varwere vane contraindications kune yakajairwa kurapwa.

Rimegepant ariCalcitoninGene-inoenderana nePeptide Receptor Antagonist. Iyo nzira yekuita yerimegepant yakaita seaCalcitoninGene-inoenderana nePeptide Receptor Antagonist.